Tristel plc (AIM: TSTL), the AIM-listed manufacturer of infection prevention products, has announced it will present and exhibit at the Mello2026 investor event on Wednesday 18 November at The Clayton Hotel & Conference Centre, Chiswick High Road, London. Chief Executive Officer Chris Lee and Chief Financial Officer Anna Wasyl will deliver two presentations during the day. The company has confirmed that no new information will be disclosed at the event, with a PDF of the presentation to be made available on Tristel's investor relations website following the sessions.

Key Points

  • Tristel plc (AIM: TSTL) — AIM-listed global infection prevention company headquartered in Snailwell, near Cambridge
  • CEO Chris Lee and CFO Anna Wasyl will present at 9:00am and 13:50pm at Mello2026 on 18 November 2026
  • The company confirmed no new information will be disclosed; presentation slides will be published at investors.tristel.com
  • Investors may wish to monitor the company's investor hub for the published presentation following the event

Tristel's CEO and CFO to Outline Company Strategy at Mello2026 London Conference

Tristel has confirmed that Chris Lee, Chief Executive Officer, and Anna Wasyl, Chief Financial Officer, will jointly present at two scheduled slots — 9:00am and 13:50pm — during the Mello2026 event. The sessions are described as providing an overview of the company and its strategy. The announcement explicitly states that no new information will be disclosed at the event, meaning investors should not anticipate any fresh trading updates, financial guidance, or strategic announcements emerging from the presentations. A PDF copy of the slides will subsequently be made available on Tristel's investor hub at investors.tristel.com.

Tristel's Proprietary Chlorine Dioxide Chemistry and Global Medical Device Decontamination Market

Tristel describes itself as a global infection prevention company focused on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO2) chemistry. The company is a market leader in the manual decontamination of medical devices, supplying hospitals under the Tristel brand. Its product range also encompasses a sporicidal surface disinfection line, positioned as a sustainable alternative to commonly used pre-wetted plastic wipes. The company operates from its head office and manufacturing facility in Snailwell, near Cambridge, employing approximately 280 people across 16 subsidiaries selling into more than 40 countries.

Tristel Targets Double-Digit Revenue Growth and 25% Adjusted EBITDA Margin

According to the announcement, Tristel targets double-digit revenue growth annually alongside an adjusted EBITDA margin of at least 25%. The company states it is profitable, carries no debt, and operates a progressive dividend policy. Tristel has been listed on the London Stock Exchange's AIM market since 2005. These financial targets provide context for investors attending or reviewing materials from the Mello2026 event, though no updated performance figures or revised guidance were included in this announcement.